SENIOR CONVERTIBLE NOTE DUE February 13, 2025Allarity Therapeutics, Inc. • February 14th, 2024 • Pharmaceutical preparations • Delaware
THIS SENIOR CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Senior Convertible Notes of Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), having its principal place of business at 24 School Street, 2nd Floor, Boston, MA 02108, designated as its Senior Convertible Note due February 13, 2025 (this note, the “Note” and, collectively with the other notes of such series, the “Notes”).
LIMITED WAIVER AGREEMENTLimited Waiver Agreement • February 14th, 2024 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
THIS LIMTIED WAIVER AGREEMENT (this “Agreement”), dated as of February 13, 2024, is by and between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (the “Purchasers”). Capitalized terms used herein and not defined shall have the meaning set forth in the Purchase Agreement (defined below).
